Bravo, Dr. J…. I think we are all extremely impr
Post# of 144793
![Avatar](/images/ProfileImages/1958288915_69748_MIM-104.png)
Please excuse my ignorance. After his last letter to the shareholders this morning, I wonder why suddenly we have this priority of a Phase II study of Leronlimab in patients with relapsed/refractory microsatellite stable Colorectal Cancer/CRC.
Then, if you check this article below on using immunotherapies for CRC, you can tell that so many monoclonal antibodies/MABs are being used already (See Tables 3 & 4) except Leronlimab.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10963412/
But the CRC market isn’t that big if you check the link below.
https://colorectalcancer.org/article/acs-rele...rQEALw_wcB
Just a question here and no intention to be a stock pumper. Is it because we have potential partners, whom they want to see what Leronlimab can do in their combined trials after a Phase II study?
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)